Adalvo is pleased to announce that we have extended our strategic partnership with Bioventure, the subsidiary of Healthcare Division of Yas Holding, signing a licensing deal for four molecules, within the MENA region.
The products are indicated in a variety of treatments including oncology, urinary tract infection, and anti-infective.
With this collaboration, Adalvo is now able to offer over 30 products within GCC & North Africa, extending our coverage within the region.
We expect to continue strengthening our position within this market, providing patients with high-quality and affordable options for their treatments, together with our partners.
We are thrilled to be extending our strategic collaboration with Bioventure, with the addition of four differentiated molecules. Bioventure has been an early supporter of Adalvo, ever since our inception, and this longstanding partnership is key in further strengthening our commercial presence across the globe. We look forward to working with Bioventure to bring essential treatments to patients in need
Collaboration with Adalvo is another step forward in the development and patient access improvement in the MENA region. We look forward to contribute to patients well-being and expand the variety and affordability of required high-quality treatments, with our strategic partner - Adalvo.